Société Nationale des Pétroles du Congo (SNPC) Outlines Congo's Gas Master Plan
The GMP was outlined by Dr. Bi-Dia-Ayo Ibata, Head of Associations Division and Supervisory Relations, SNPC during a Vision Congo&Gas Master Plan Technical Session on Day 0 of the inaugural Congo Energy&Investment Forum in Brazzaville.
'The main objective of the Gas Master Plan is to develop an exploration strategy in the short- and long-term to contribute to the development of natural resources and contribute to economic diversification,' Ibata stated, adding, 'The five main objectives are resource maximization, economic growth and diversification, social benefits, government revenue and attracting investment.'
According to the GMP, gas-to-power should remain a priority for the country, with low gas prices to support sustainable growth. New industrial projects and LPG supply solutions are also recommended. A natural gas aggregator – potentially the SNPC – could balance the domestic market and prioritize strategic sectors. The plan also stresses the importance of the development of a natural gas policy, which will be essential for guiding sector growth.
During the session, a presentation by the country's Ministry of Hydrocarbons explored the gas potential of Congo and how a national strategy will help boost production, realize project development and drive electrification in the country.
'The strategic objective of this strategy is to increase production of liquid and gas hydrocarbons. We aim to valorize hydrocarbons by taking profit from exports and local processing,' stated Hippolyte Tchininanga, Director General of Gaz Valorization, Ministry of Hydrocarbons.
Meanwhile, the Ministry also presented its vision for a new Gas Code, which is expected to be released soon. The code aims to create an enabling, attractive environment for foreign investment to contribute to the development of natural gas. The Gas Code will also govern the legal and regulatory terms of natural gas exploration and development in Congo.
'The scope of the upcoming Gas Code includes exploration activities, development, exploitation, aggregation, collection, transport and storage of natural gas,' stated Faida Ebenga, Administrative and Legal Advisor at the Ministry of Hydrocarbons, adding, 'Approval of the Gas Code is imminent. We consider the Gas Code ready to be transmitted to the Secretary General of the government for approval.'
One of Congo's flagship natural gas projects is energy supermajor Eni's Congo LNG project. With a planned capacity of 2.4 million tons per annum, the project provides 70% of the country's electricity through natural gas. Phase 2 of the Congo LNG project is currently under construction.
'Phase 2 is being executed right now. As part of the project, we aim to have 38 new wells in development. We want to install six new wellhead platforms, one new separation and boosting hub, a new onshore gas pre-treatment plant, two FLNG facilities and finally have a liquefaction capacity of 3 million tons per annum,' stated Alberto Nocerino, Technical Director, Eni Congo.
Distributed by APO Group on behalf of Energy Capital&Power.
The inaugural Congo Energy&Investment Forum, set for March 24-26, 2025, in Brazzaville, under the highest patronage of President Denis Sassou Nguesso and supported by the Ministry of Hydrocarbons and Société Nationale des Pétroles du Congo, brings together international investors and local stakeholders to explore national and regional energy and infrastructure opportunities.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Arabian Post
a day ago
- Arabian Post
Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences real estate market on the Chinese mainland
HONG KONG SAR – Media OutReach Newswire – 1 August 2025 –Cushman & Wakefield, a leading global real estate services firm, today released itsreport. It is based on in-depth interview surveys we conducted on professionals active in the life sciences sector on the Chinese mainland. The life sciences industry on the Chinese mainland is undergoing a transformative phase, driven by progressive policies, groundbreaking innovations, the emergence of influential life sciences companies, and strategic regional development. This report delves into the latest trends shaping the sector. Policy Landscape – National and Local Catalysts Reforms enacted in 2024-2025 have significantly accelerated sector development. Nationally, China relaxed restrictions on foreign investment in gene and cell therapy and allowed the establishment of wholly foreign-owned hospitals in key cities. Regulatory incentives – such as data protection and marketing exclusivity – have improved market access for innovative drugs. Locally, cities like Beijing, Shanghai, Shenzhen, Guangzhou, and Suzhou are rolling out targeted subsidies, fast-track approvals, and ecosystem-building programmes that directly benefit biotech development. ADVERTISEMENT Recent national policy initiatives on the Chinese mainland Types of policies Detail information Opening to Foreign Investment In 2024, China eased restrictions on foreign investments in stem cell research, gene therapy, and genetic diagnostics within Free Trade Zones (FTZs) like Beijing, Shanghai, Guangdong, and Hainan. Regulatory Incentives The State Council's Circular No. 53 introduced measures such as regulatory data protection and marketing exclusivity for select pharmaceutical products, including orphan and paediatric drugs. Wholly Foreign-Owned Hospitals China now permits the establishment of wholly foreign-owned hospitals in cities like Beijing, Shanghai, and Shenzhen, enhancing healthcare services and encouraging foreign investment. Source: Cushman & Wakefield Research Industry Innovation and Company Growth Chinese life sciences companies are moving beyond generic drug manufacturing toward innovative therapies. Firms like Akeso, BeiGene, Gracell, and Legend Biotech are now global players, leading in CAR-T, bispecific antibodies, and AI-assisted R&D. These companies are not only commercialising cutting-edge treatments but also attracting international investment and licensing agreements, reinforcing the Chinese mainland's global relevance in life sciences. Real Estate Development and Regional Hubs ADVERTISEMENT Innovation hubs such as Suzhou BioBAY, Zhangjiang Hi-Tech Park (Shanghai), and the Bioisland Innovation Centre (Guangdong) are central to regional clustering. These hubs offer end-to-end support, including shared labs, venture capital access, GMP-compliant facilities, and proximity to academic and clinical networks. The rise of second-tier innovation cities like Chengdu and Ningbo further expands growth corridors. The 'R&D + Manufacturing + Service' ecosystem Source: Cushman & Wakefield Research Landlord Perspectives – Evolving Real Estate Models Real estate developers and landlords are adapting to sector-specific requirements through asset-light models, flexible leasing, and high-specification lab and production space. Tier-1 cities face saturation, but central and western regions exhibit healthy demand. Developers are incorporating advanced sustainability and compliance features to meet growing regulatory and ESG expectations, particularly in GMP and cleanroom environments. Digitalisation, environmental policies, and differentiated tenant strategies are shaping performance. Operators now focus on integrated ecosystems with platforms that link tenants to R&D services, policy benefits, and technology partners. Occupier Perspectives – Growth, Innovation, and Challenges Life sciences occupiers are navigating regulatory reform, rising compliance demands, and intensified market competition. Many are localising production and R&D, leveraging regional subsidies, and investing in AI-powered innovation platforms. Occupiers seek flexibility, proximity to talent and infrastructure, and co-located R&D and manufacturing to support accelerated innovation and operational agility. In real estate, demand is strongest for GMP-certified labs, modular production facilities, and shared innovation platforms. Occupiers emphasise location advantages, sustainability certifications (e.g., LEED, WELL), and integration into clusters that enable faster time-to-market. Tony Su, Managing Director, National Head of Industrial & Logistics Property Services, China, said, 'Life sciences business parks on the Chinese mainland demonstrated clear regional differentiation, highlighting opportunities for strategic positioning. While Tier-1 cities saw more moderate performance due to broader macroeconomic factors and abundant supply, core cities in central and western regions recorded healthy occupancy rates, underpinned by strong industrial clustering and increasingly sophisticated ecosystems – contributing to steady growth in asset value.' Johnathan Wei, President, Project & Occupier Services, China, said, 'Several interviewed life sciences companies on the Chinese mainland achieved revenue growth supported by innovative products and favourable policy tailwinds. While overall growth remained modest for many, a select group reported strong performance, highlighting opportunities for differentiation'. Andrew Chan, Managing Director, Head of Valuation & Advisory Services, Greater China, said,' Looking ahead to 2025 and beyond, growth opportunities lie in AI-driven drug discovery, personalised medicine, advanced therapeutics (CGT, RNA), and green-certified facilities. Government policies continue to support innovation through fast-track approvals, rare disease funding, and subsidies aligned with dual-carbon and ESG goals'. Shaun Brodie, Head of Research Content, Greater China, 'Life sciences real estate is shifting from generic parks to specialised, digitally enabled campuses with high compliance and flexibility. Investment strategies increasingly emphasise long-term partnerships, collaborative operating models, and digital infrastructure. Both landlords and occupiers express cautious optimism, with strategic differentiation and regional targeting seen as keys to unlocking future value'. Please click here to download the full report. Hashtag: #Cushman&Wakefield The issuer is solely responsible for the content of this announcement. About Cushman & Wakefield Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for property owners and occupiers with approximately 52,000 employees in nearly 400 offices and 60 countries. In Greater China, a network of 23 offices serves local markets across the region. In 2024, the firm reported revenue of $9.4 billion across its core services of Valuation, Consulting, Project & Development Services, Capital Markets, Project & Occupier Services, Industrial & Logistics, Retail, and others. Built around the belief that Better never settles, the firm receives numerous industry and business accolades for its award-winning culture. For additional information, visit or follow us on LinkedIn (

Zawya
22-07-2025
- Zawya
Democratic Republic of the Congo (DRC) Hydrocarbons Ministry to Lead High-Level Delegation at United States (U.S.)-Africa Energy Forum (USAEF) 2025
The Democratic Republic of the Congo (DRC) is intensifying its focus on upstream development and strategic U.S. partnerships ahead of the U.S.-Africa Energy Forum (USAEF) 2025 ( taking place on August 6-7 in Houston. Leading the effort is a senior delegation from the Ministry of Hydrocarbons, delivering a clear message: the DRC is open for investment, with exploration and downstream development as top priorities. As part of its hydrocarbons roadmap, the DRC is seeking partners to bring capital, technology, and expertise into its exploration efforts, with a focus on high-potential onshore and offshore blocks. Many of these basins – including the Cuvette Centrale and Coastal regions – remain underexplored. While the DRC currently produces around 18,000 barrels per day (bpd), the Ministry of Hydrocarbons is targeting a major production scale-up to 300,000 bpd. This growth is expected to be driven by new offshore discoveries and a forthcoming petroleum code designed to clarify investor terms and enable joint development ventures. The Ministry is also seeking to engage U.S.-based downstream and petrochemicals companies as part of a broader push to expand value-added processing and strengthen domestic energy infrastructure. USAEF 2025 offers a key platform for direct dialogue with U.S. investors, paving the way for new deals, technical partnerships and cross-regional energy trade. Current initiatives include the development of a new oil terminal in Goma to stabilize fuel supply in the east, along with upgrades to fuel storage and distribution networks nationwide. These projects create strong opportunities for U.S. engineering, technology and EPC firms to support infrastructure modernization, modular refining and local capacity-building. Under efforts to foster new technical partnerships and attract capital investment, the Ministry will hold meetings at USAEF 2025 with upstream operators, seismic and drilling service providers, and petrochemical firms interested in entering or expanding in the Congolese market. The DRC is positioning itself as a strategic partner for American energy companies seeking access to a frontier market with significant geological potential, a reform-minded government and growing regional demand for refined products and petrochemicals. For tickets, sponsorship opportunities and more information, please contact sales@ or visit Join us in Houston to connect with the leaders shaping Africa's energy landscape and experience the momentum that drives ECP's events worldwide. Distributed by APO Group on behalf of Energy Capital&Power.


Zawya
14-07-2025
- Zawya
Saudi: SFDA suspends European pharmaceutical factory over critical GMP violations
RIYADH — The Saudi Food and Drug Authority (SFDA) has suspended the registration of a European pharmaceutical factory following the discovery of serious violations of Good Manufacturing Practices (GMP) during an external inspection. The decision came after SFDA inspectors identified fundamental lapses in the factory's manufacturing procedures and internal quality systems, posing a direct risk to the safety of pharmaceutical products intended for export to Saudi Arabia. The suspension was enacted as a precautionary measure to prevent the distribution of potentially unsafe medicines in the Kingdom. The inspection, conducted under the SFDA's foreign factory oversight program, aligns with international regulatory standards and involved a comprehensive review of the facility's manufacturing operations, quality controls, and distribution protocols. Several European regulatory agencies have since reached out to the SFDA to examine its technical findings and take further actions, reflecting growing international recognition of the SFDA's regulatory rigor and global role in pharmaceutical safety. The Authority stressed that the monitoring of overseas manufacturing sites is a key pillar of its regulatory framework and is carried out independently using scientific and technical data. It reaffirmed its commitment to consumer safety and pledged to continue taking decisive action against any manufacturer found to be in violation of safety protocols. © Copyright 2022 The Saudi Gazette. All Rights Reserved. Provided by SyndiGate Media Inc. (